Riskpilot← Back to searchSign inGet full accessPharmera Gothia Pharmaceutical AB
ABActiveOrg 5566640693Skårsgatan 34Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20040 employees
Revenue 2024
SEK 1
-200% vs 2023
EBITDA margin
-1374400.0%
+90% vs 2023
Equity ratio
25.1%
Financial strength
Net profit 2024
SEK 100K
+506% vs 2023
| Revenue | SEK 1 | -200% |
| EBITDA | SEK -14K | +90% |
| Net profit | SEK 100K | +506% |
| Total assets | SEK 1,7M | +7% |
| Equity | SEK 417K | +32% |
| Employees | 0 | — |
Legal name
Pharmera Gothia Pharmaceutical AB
Org number
5566640693
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14 juli 2004
Share capital
SEK 102 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva handel, såväl import som export med läkemedel och därmed förenlig verksamhet såsom handel med medicinsk utrustning och apoteksvaror.
Address
Skårsgatan 34
Email
info@pharmeragroup.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | −0 | −0 | 0 |
| Staff expenses | — | — | −0 | −0 | −0 |
| EBITDA | −207 | 1 | −32 | −145 | −14 |
| Depreciation & amort. | −4 | −0 | — | — | — |
| EBIT | −211 | 1 | −32 | −145 | −14 |
| Net financials | — | — | — | 161 | 114 |
| Profit before tax | −211 | 1 | −32 | 17 | 100 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −211 | 1 | −32 | 17 | 100 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 422 | 1 423 | 1 427 | 1 548 | 1 660 |
| Equity | 331 | 332 | 300 | 317 | 417 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 091 | 1 091 | 1 127 | 1 232 | 1 244 |
| Total debt | 1 091 | 1 091 | 1 127 | 1 232 | 1 244 |
EBITDA margin
-1374400.0%
This company
15.8%
Market median
-8698834% vs market
20202024
Equity ratio
25.1%
This company
38.2%
Market median
-34% vs market
20202024
Return on equity
24.0%
This company
18.4%
Market median
+30% vs market
20202024
Net profit margin
9998700.0%
This company
8.1%
Market median
+123440641% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
2.99×
This company
0.62×
Market median
-382% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LB Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (1) | ||
MC | Audit | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2021 | |
| Former (2) | ||
| Chairman | 2021 – 2021 | |
| Board of Directors | 2021 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmera Gothia Pharmaceutical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Bernhard Rydja | Chief Executive Officer | 0 companies |
| Magnus Carl-Johan Persson | Audit | 0 companies |
| Karin Birgitta Lindahl-Rydja | Deputy Board Member | 0 companies |
| Paul Robert Nilsson | Chairman | 0 companies |
| Patrik Robert Nilsson | Board of Directors | 0 companies |